Juvenile Glaucoma

Back

Background

Juvenile glaucoma is a rare juvenile-onset open-angle glaucoma (JOAG) often found associated with myopia that shows autosomal dominant transmission. This entity is one of a group of pediatric glaucomas known as primary developmental glaucoma.

Differential diagnoses of the primary developmental glaucomas

Primary congenital glaucoma

Autosomal-dominant juvenile open-angle glaucoma

Primary angle-closure glaucoma

Primary glaucoma associated with systemic abnormalities

Primary glaucoma associated with ocular abnormalities

Secondary acquired glaucomas in the pediatric age group

Traumatic glaucoma

Glaucoma secondary to intraocular neoplasm

Glaucoma secondary to chronic uveitis

Lens-related glaucoma

Glaucoma following lensectomy for congenital cataracts

Steroid-induced glaucoma

Glaucoma secondary to rubeosis

Secondary angle-closure glaucoma

Malignant glaucoma

Glaucoma associated with increased venous pressure

Glaucoma secondary to intraocular infection

Glaucoma secondary to undetermined etiology

Pathophysiology

Increased intraocular pressure (IOP) is caused by impaired outflow of aqueous humor through the trabecular meshwork into the Schlemm canal. On clinical examination with gonioscopy, the filtration tissues within the anterior chamber angle appear normal in persons with juvenile glaucoma.[2] Pathologic examination has found thickened tissue and abnormal deposit of extracellular tissue in the trabecular meshwork between the anterior chamber and the Schlemm canal.

Following recognition of linkage of the gene for juvenile glaucoma on chromosome 1 (band 1q21-q31), the gene itself was identified and related to mutations found in the trabecular meshwork inducible glucocorticoid response (TIGR) gene in patients with juvenile glaucoma. This gene, now called myocilin, codes for the glycoprotein myocilin that is found in the trabecular meshwork and other ocular tissues. The normal function of myocilin and its role in causing glaucoma is undetermined. In studies of consanguineous populations, Khan et al concluded that mutation in CYP1B1 rather than mutation in MYOC can sometimes underlie familial primary juvenile glaucoma.[3, 4, 5]

Epidemiology

Frequency

United States

Juvenile glaucoma has an estimated occurrence of 1 per 50,000 persons. It is rare when compared in frequency to other types of childhood glaucoma.

Mortality/Morbidity

No risk of mortality exists with juvenile glaucoma. Loss of vision is possible without early diagnosis and treatment.

Race

Juvenile glaucoma has been observed in Japanese, French, French Canadian, Caucasian-American, Asian-American, Hispanic-American, African-American, Panamanian, German, English, Irish, Danish, Italian, and Spanish families.

Young black patients with juvenile glaucoma, especially when myopic, are more susceptible to glaucomatous damage than are whites.[6]

Sex

Juvenile glaucoma probably occurs with equal frequency and severity in males and females.

Age

Patients with juvenile glaucoma show no evidence of congenital or infantile glaucoma. When candidate children are monitored carefully in families with a history of glaucoma, the onset of abnormal eye pressures occurs in children aged 5-10 years. In sporadic patients or those with no known family history of juvenile glaucoma, recognition of this glaucoma has occurred more often in adolescence or during the early adult years.

Prognosis

With an early diagnosis of glaucoma, the prognosis is excellent for retention of vision in patients.[7, 8]

Patient Education

Family members of patients with juvenile glaucoma must be informed of their risk and the risk of glaucoma in offspring.

For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education articles Glaucoma Overview, Glaucoma Medications, and Glaucoma FAQs.

History

Because patients with juvenile glaucoma are often asymptomatic, the diagnosis is sometimes made on routine ophthalmological examination when optic nerve abnormalities are noted. Symptoms of visual loss and headache may lead to discovery of the disease.

A family history of glaucoma with occurrence over 2 generations or in a parent and sibling often is responsible for an early diagnosis of juvenile glaucoma. Patients are asymptomatic until glaucoma is advanced. Myopia is present in 50% of persons with juvenile glaucoma.

Physical

General physical examination findings are normal.

Causes

Juvenile glaucoma is caused by a genetically determined defect in the trabecular meshwork with autosomal dominant transmission (see Pathophysiology).

Physical Examination

Physical examination of the visual system may include elevated intra-ocular pressures, optic nerve atrophy or cupping, asymmetry of the optic nerve heads, and visual field loss.

Laboratory Studies

Mutational analysis of the myocilin gene at chromosomal region 1q21-q31 can be performed. More than 50% of disease-causing alleles may be screened by restriction enzyme analysis.

Imaging Studies

Glaucoma assessment - Field testing, fundus photography, and retinal tomography

Procedures

See Physical.

Histologic Findings

An isolated report by Tawara and Inomata found an abnormal compact trabecular meshwork in patients with juvenile glaucoma.[9]

Approach Considerations

Treatment of juvenile glaucoma involves lowering of intra-ocular pressure pharmacologically or/and surgically.

Medical Care

Glaucoma medications may temporally control IOP. Often, a rising eye pressure over 1-3 years may become resistant to all medications and dictate a need for eye surgery.

Surgical Care

Operations found useful for adult-onset open-angle glaucoma are useful in juvenile glaucoma. In addition, goniotomy is an effective procedure for this disease in both children and adults.

Consultations

Consultation with an ophthalmologist familiar with this rare type of  glaucoma  may be helpful.

Activity

No limitations on activity are necessary. When vision remains only in one eye, protection of the remaining seeing eye is mandatory.

Long-Term Monitoring

Repetitive regular eye examinations are indicated indefinitely after the diagnosis of juvenile glaucoma.

Reexamination of the eyes is indicated for those candidate children with a family history of juvenile glaucoma or with myopia and borderline IOPs.

Further Inpatient Care

Careful observation is indicated after glaucoma surgery.

Inpatient and Outpatient Medications

As dictated by IOPs, antiglaucoma medications may be indicated.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity (visual loss due to optic nerve damage). These are applied topically to the eye.

Latanoprost (Xalatan, Xelpros)

Clinical Context:  May increase the outflow of aqueous humor. Patients should be informed about possible cosmetic effects to the eye/eyelashes, especially if uniocular therapy is to be initiated.

Bimatoprost (Latisse, Lumigan)

Clinical Context:  This agent is a prostamide analogue with ocular hypotensive activity. It mimics the IOP-lowering activity of prostamides via the prostamide pathway. Bimatoprost ophthalmic solution is used to reduce IOP in open-angle glaucoma and ocular hypertension. Applied topically once a day prior to bed.

Travoprost ophthalmic (Travatan Z)

Clinical Context:  This agent is a prostaglandin F2-alpha analogue (FP). It is a selective FP prostanoid receptor agonist that is believed to reduce IOP by increasing uveoscleral outflow. Travoprost ophthalmic solution is used to treat open-angle glaucoma and ocular hypertension. Applied topically once a day prior to bed.

Tafluprost (Zioptan)

Clinical Context:  Tafluprost is a topical, preservative-free, ophthalmic prostaglandin analogue that is indicated for elevated IOP associated with open-angle glaucoma or ocular hypertension. The exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow. Applied topically once a day prior to bed.

Class Summary

For reduction of IOP in patients intolerant to other IOP-lowering medications or who have failed to respond optimally to other IOP-lowering medications.

Timolol ophthalmic (Timoptic, Timoptic XE, Betimol, Istalol)

Clinical Context:  Timolol may reduce elevated and normal IOP, with or without glaucoma, by reducing the production of aqueous humor. Timolol gel-forming solution (Timoptic XE) usually is administered at night, unless it is used concurrently with latanoprost therapy. Used as 0.25% or 0.5% solution and applied topically to the eye 1-2 times per day.

Levobunolol (Betagan)

Clinical Context:  Levobunolol is a nonselective beta adrenergic blocking agent that lowers IOP by reducing aqueous humor production and possibly increasing the outflow of aqueous humor.

Metipranolol

Clinical Context:  Metipranolol is a beta adrenergic blocker that has little or no intrinsic sympathomimetic effect and membrane-stabilizing activity. It also has little local anesthetic activity. The drug reduces IOP by reducing the production of aqueous humor.

Class Summary

These agents decrease aqueous production, possibly by blocking adrenergic beta receptors present in the ciliary body. Unfortunately, the nonselective medications in this class also interact with the beta receptors in the heart and lungs, causing significant adverse effects.

Brimonidine (Alphagan P)

Clinical Context:  Brimonidine is a relatively selective alpha2 adrenergic-receptor agonist that decreases IOP by dual mechanisms, reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine has minimal effect on cardiovascular and pulmonary parameters. A moderate risk of allergic response to this drug exists. Caution should be used in individuals who have developed an allergy to Iopidine. IOP lowering of up to 27% has been reported. Applied topically 2-3 times a day.

Class Summary

Alpha agonists work to both decrease production of fluid and increase drainage.

Dorzolamide (Trusopt)

Clinical Context:  Dorzolamide is a reversible carbonic anhydrase inhibitor that may decrease aqueous humor secretion, causing a decrease in IOP. Presumably, it slows bicarbonate ion formation, producing a subsequent reduction in sodium and fluid transport.

Systemic absorption can affect carbonic anhydrase in the kidney, reducing hydrogen ion secretion at the renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water. Dorzolamide is less stinging on instillation secondary to buffered pH. Applied 2-3 times per day.

Brinzolamide (Azopt)

Clinical Context:  Brinzolamide catalyzes a reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. It may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, administer them at least 10 minutes apart. Applied 2-3 times per day.

Methazolamide (Neptazane)

Clinical Context:  Methazolamide reduces aqueous humor formation by inhibiting the enzyme carbonic anhydrase, which results in decreased IOP. Oral carbonic anhydrase inhibitors have significant adverse effects, including tiredness, malaise, and anorexia. Because of an increased incidence of adverse effects, it is rarely indicated for the treatment of ocular hypertension.

Class Summary

By slowing the formation of bicarbonate ions, causing a reduction in sodium and fluid transport, these agents may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP. Carbonic anhydrase inhibitors typically have a weaker effect than beta blockers.

Brinzolamide/brimonidine (Simbrinza)

Clinical Context:  This combination product contains the carbonic anhydrase inhibitor brinzolamide and the alpha2 adrenergic receptor agonist brimonidine. It is indicated for reduction of elevated intraocular pressure in patients with primary open-angle glaucoma.

Timolol/brimonidine (Combigan)

Clinical Context:  Brimonidine is a selective alpha2 adrenergic receptor agonist and timolol is a nonselective beta-adrenergic receptor inhibitor. Each of these agents decrease elevated IOP, whether or not associated with glaucoma.

Timolol/dorzolamide (Cosopt)

Clinical Context:  Dorzolamide is a carbonic anhydrase inhibitor that decreases aqueous humor secretion, causing a decrease in IOP. This agent presumably slows bicarbonate ion formation with subsequent reduction in sodium and fluid transport. Timolol is a nonselective beta-adrenergic receptor blocker that decreases IOP by decreasing aqueous humor secretion.

Class Summary

Combination solution may further decrease aqueous humor secretion compared to each solution used as monotherapy, while improving compliance. These agents have been approved by the FDA for children aged 2 years or older.

Acetazolamide (Diamox Sequels)

Clinical Context:  Acetazolamide is primarily used for the treatment of refractory POAG and secondary glaucomas.  Oral carbonic anhydrase inhibitors have significant adverse effects, including tiredness, malaise, and anorexia. Because of an increased incidence of adverse effects, it is rarely indicated for the treatment of ocular hypertension.

Methazolamide (Neptazane)

Clinical Context:  Methazolamide reduces aqueous humor formation by inhibiting the enzyme carbonic anhydrase, which results in decreased IOP. Oral carbonic anhydrase inhibitors have significant adverse effects, including tiredness, malaise, and anorexia. Because of an increased incidence of adverse effects, it is rarely indicated for the treatment of ocular hypertension.

Class Summary

By slowing the formation of bicarbonate ions, causing a reduction in sodium and fluid transport, these agents may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP. Carbonic anhydrase inhibitors typically have a weaker effect than beta blockers.

Netarsudil ophthalmic (Rhopressa)

Clinical Context:  Netarsudil ophthalmic solution 0.02% is a newly approved (2018) rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has not been evaluated for the treatment of juvenile glaucoma.

Class Summary

Agents in this class may reduce intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork route.

Author

Andrew A Dahl, MD, FACS, Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Martin B Wax, MD, Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Research and Development, Head, Ophthalmology Discovery Research and Preclinical Sciences, Alcon Laboratories, Inc

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

David Sellers Walton, MD, Clinical Professor of Ophthalmology, Harvard Medical School; Surgeon in Ophthalmology, Massachusetts Eye and Ear Infirmary; Assistant Pediatrician, Massachusetts General Hospital

Disclosure: Nothing to disclose.

Gerhard W Cibis, MD, Clinical Professor, Director of Pediatric Ophthalmology Service, Department of Ophthalmology, University of Kansas School of Medicine

Disclosure: Nothing to disclose.

References

  1. Urban B, Bakunowicz-Łazarczyk A, Michalczuk M, Krętowska M. Evaluation of corneal endothelium in adolescents with juvenile glaucoma. J Ophthalmol. 2015. 2015:895428. [View Abstract]
  2. Cronemberger S, Calixto N, Avellar Milhomens TG, Gama PO, Milhomens EG, Rolim H, et al. Effect of intraocular pressure control on central corneal thickness, horizontal corneal diameter, and axial length in primary congenital glaucoma. J AAPOS. 2014 Oct. 18 (5):433-6. [View Abstract]
  3. Khan AO. Genetics of primary glaucoma. Curr Opin Ophthalmol. 2011 Sep. 22(5):347-55. [View Abstract]
  4. Khan AO, Al-Abdi L, Mohamed JY, Aldahmesh MA, Alkuraya FS. Familial juvenile glaucoma with underlying homozygous p.G61E CYP1B1 mutations. J AAPOS. 2011 Apr. 15(2):198-9. [View Abstract]
  5. Souzeau E, Hayes M, Zhou T, Siggs OM, Ridge B, Awadalla MS, et al. Occurrence of CYP1B1 Mutations in Juvenile Open-Angle Glaucoma With Advanced Visual Field Loss. JAMA Ophthalmol. 2015 Jul 1. 133 (7):826-33. [View Abstract]
  6. Lotufo D, Ritch R, Szmyd L Jr, Burris JE. Juvenile glaucoma, race, and refraction. JAMA. 1989 Jan 13. 261 (2):249-52. [View Abstract]
  7. Aponte EP, Diehl N, Mohney BG. Medical and surgical outcomes in childhood glaucoma: a population-based study. J AAPOS. 2011 Jun. 15(3):263-7. [View Abstract]
  8. de Silva DJ, Khaw PT, Brookes JL. Long-term outcome of primary congenital glaucoma. J AAPOS. 2011 Apr. 15(2):148-52. [View Abstract]
  9. Tawara A, Inomata H. Developmental immaturity of the trabecular meshwork in juvenile glaucoma. Am J Ophthalmol. 1984 Jul 15. 98(1):82-97. [View Abstract]
  10. Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF, Junqua D, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med. 1998 Apr 9. 338(15):1022-7. [View Abstract]
  11. Bruttini M, Longo I, Frezzotti P, Ciappetta R, Randazzo A, Orzalesi N, et al. Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch Ophthalmol. 2003 Jul. 121(7):1034-8. [View Abstract]
  12. Gupta V, Dutta P, Ov M, Kapoor KS, Sihota R, Kumar G. Effect of glaucoma on the quality of life of young patients. Invest Ophthalmol Vis Sci. 2011 Oct. 52(11):8433-7. [View Abstract]
  13. Melamed S, Ashkenazi I. Juvenile-onset open angle glaucoma. Albert D, Jakobiec F, ed. Principles and Practice of Ophthalmology. Philadelphia: WB Saunders Co; 1994. 1345-9.
  14. Puska P, Lemmela S, Kristo P, Sankila EM, Jarvela I. Penetrance and phenotype of the Thr377Met Myocilin mutation in a large Finnish family with juvenile- and adult-onset primary open-angle glaucoma. Ophthalmic Genet. 2005 Mar. 26(1):17-23. [View Abstract]
  15. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997 Jan 31. 275(5300):668-70. [View Abstract]
  16. Tamm ER, Russell P. The role of myocilin/TIGR in glaucoma: results of the Glaucoma Research Foundation catalyst meeting in Berkeley, California, March 2000. J Glaucoma. 2001 Aug. 10(4):329-39. [View Abstract]
  17. Tsai JC, Chang HW, Kao CN, Lai IC, Teng MC. Trabeculectomy with mitomycin C versus trabeculectomy alone for juvenile primary open-angle glaucoma. Ophthalmologica. 2003 Jan-Feb. 217(1):24-30. [View Abstract]
  18. Wiggs JL, Del Bono EA, Schuman JS, Hutchinson BT, Walton DS. Clinical features of five pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31. Ophthalmology. 1995 Dec. 102(12):1782-9. [View Abstract]